web analytics

Senescent Epithelial Cell Targeting and Microbiota Therapy for IBD

Lead Inventor: Yanchun Li

SUMMARY

Improved inflammatory bowel disease (IBD) management by identifying and therapeutically targeting senescent colonic epithelial cells, thereby reducing mucosal inflammation through depletion of these pro-inflammatory cells

The Unmet Need: Insufficient therapeutic targeting of epithelial components in inflammatory bowel disease

  • Inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, is a chronic gastrointestinal inflammatory disorder with increasing prevalence worldwide and substantial healthcare and socioeconomic burdens; current treatments focus predominantly on immune system modulation, lacking effective biomarkers and therapies addressing the epithelial compartment that contributes significantly to disease pathology.

  • The broader biomedical trend emphasizes precision targeting of cellular and molecular disease drivers beyond immune modulation, supported by advances in identifying cellular senescence and microenvironmental factors as key contributors to chronic inflammatory conditions, thereby opening new avenues for innovative therapeutic interventions.

The Proposed Solution: Therapeutic depletion of senescent colonic epithelial cells using BCL-2 family inhibitors to mitigate IBD-associated inflammation

  • The faculty inventor established colonic epithelial senescence as a novel biomarker and drug target in IBD, employing small-molecule agents to selectively eliminate senescent epithelial cells that produce pro-inflammatory cytokines and chemokines contributing to mucosal inflammation; this strategy differs from existing immune-focused therapies by directly addressing epithelial cell senescence and has demonstrated preclinical validation with significant reduction of mucosal inflammation and colitis development in experimental models, proposing its combined use with immune-targeting treatments for comprehensive disease management.

ADVANTAGES

  • Novel biomarker identification for precise disease monitoring

  • Targeted depletion of pro-inflammatory senescent epithelial cells

  • Complementary mechanism to existing immune therapies

  • Preclinical validation demonstrating efficacy in reducing inflammation

  • Potential applicability across major IBD subtypes

  • Utilization of existing small-molecule drugs for repurposing

APPLICATIONS

  • Therapeutic intervention for ulcerative colitis

  • Treatment of Crohn’s disease to attenuate mucosal inflammation

  • Adjunctive therapy combined with immune-modulating agents for comprehensive IBD management

PUBLICATIONS